Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 15/20 | 0.43 |
| ▸ | CBFB | Q13951 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | MPI | P34949 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29870122 | 1.00 | MET (0.43) | METCBFBKDM4EMAPTL3MBTL1 | |
| SCHEMBL29870124 | 0.83 | MET (0.42) | METKDM4EMAPTL3MBTL1MPI | |
| SCHEMBL1329076 | 0.83 | MET (0.42) | METKDM4EMAPTNR4A2 | |
| SCHEMBL28864789 | 0.83 | MET (0.42) | METKDM4EMAPTL3MBTL1MPI | |
| SCHEMBL28150885 | 0.83 | MET (0.45) | METKDM4EMAPTNR4A2 | |
| SCHEMBL1329756 | 0.81 | PTGDR2 (0.46) | METKDM4EMAPT | |
| Hydrochloric Acid SCHEMBL20562968 | 0.81 | MET (0.41) | METKDM4EMAPTHTTSMN1; SMN2 | |
| SCHEMBL3593816 | 0.80 | MET (0.42) | METKDM4EMAPTLMNAHTT | |
| SCHEMBL1330431 | 0.79 | MET (0.43) | METNPC1 | |
| SCHEMBL10162620 | 0.78 | MET (0.43) | MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107312009-B | Quinoline compound, preparation method, intermediate, pharmaceutical composition and application thereof | 上海医药集团股份有限公司 | 2022-09-20 | — | — | CN | disclosed |
| US-8507676-B2 | Heterocyclic oxime compounds | NOVARTIS AG (CH) | 2013-08-13 | — | — | US | disclosed |
| US-8507676-B2 | Heterocyclic oxime compounds | NOVARTIS AG (CH) | 2013-08-13 | — | — | US | disclosed |
| US-8507676-B2 | Heterocyclic oxime compounds | NOVARTIS AG (CH) | 2013-08-13 | — | — | US | disclosed |
| US-8410264-B2 | Heterocyclic oxime compounds | NOVARTIS AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-8410264-B2 | Heterocyclic oxime compounds | NOVARTIS AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-8410264-B2 | Heterocyclic oxime compounds | NOVARTIS AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-20120302570-A1 | HETEROCYCLIC OXIME COMPOUNDS | NOVARTIS AG (CH) | 2012-11-29 | — | — | US | disclosed |
| US-20120302570-A1 | HETEROCYCLIC OXIME COMPOUNDS | NOVARTIS AG (CH) | 2012-11-29 | — | — | US | disclosed |
| US-20120302570-A1 | HETEROCYCLIC OXIME COMPOUNDS | NOVARTIS AG (CH) | 2012-11-29 | — | — | US | disclosed |
| CN-102574853-A | Heterocyclic oxime compounds | NOVARTIS AG | 2012-07-11 | — | — | CN | disclosed |
| EP-2467383-A1 | HETEROCYCLIC OXIME COMPOUNDS | Novartis AG (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-20110065708-A1 | HETEROCYCLIC OXIME COMPOUNDS | NOVARTIS AG (CH) | 2011-03-17 | — | — | US | disclosed |
| US-20110065708-A1 | HETEROCYCLIC OXIME COMPOUNDS | NOVARTIS AG (CH) | 2011-03-17 | — | — | US | disclosed |
| US-20110065708-A1 | HETEROCYCLIC OXIME COMPOUNDS | NOVARTIS AG (CH) | 2011-03-17 | — | — | US | disclosed |
| WO-2011020861-A1 | HETEROCYCLIC OXIME COMPOUNDS | NOVARTIS AG (CH) | 2011-02-24 | — | — | WO | disclosed |
| WO-2011020861-A1 | HETEROCYCLIC OXIME COMPOUNDS | NOVARTIS AG (CH) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065708-A1 | HETEROCYCLIC OXIME COMPOUNDS | MET, ERBB2, TIE1 | MET 1/4885CBFB 2851/4885KDM4E 684/4885 |
| US-20120302570-A1 | HETEROCYCLIC OXIME COMPOUNDS | MET, ERBB2, TIE1 | MET 1/4885CBFB 2851/4885KDM4E 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.